Rapt Therapeutics, Inc. SEC Filings

RAPT Therapeutics filed an 8‑K stating it furnished a press release announcing financial results for the quarter and nine months ended September 30, 2025. The release is included as Exhibit 99.1.

The company states the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other SEC filings.

RAPT Therapeutics announced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters will purchase shares at $28.20 each, and have a 30-day option to buy up to 1,250,000 additional shares.

The company estimates net proceeds of $234.4 million, or $269.7 million if the option is fully exercised. RAPT states that these proceeds, together with existing cash, cash equivalents and marketable securities, are expected to fund operations into 2028. Closing is expected on October 23, 2025, subject to customary conditions. The offering is being made under an effective Form S-3 and prospectus supplement.

RAPT Therapeutics launched a primary offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters have a 30‑day option to purchase up to 1,250,000 additional shares at the public price, less discounts.

Gross proceeds are $250,000,020 with underwriting discounts of $15,000,001, yielding proceeds to the company before expenses of $235,000,019. RAPT estimates net proceeds of approximately $234.4 million (or $269.7 million if the option is fully exercised). The company intends to use the funds to advance RPT904 in food allergies and chronic spontaneous urticaria, support other pipeline programs, and for working capital and general corporate purposes. Based on current plans, cash including these proceeds is expected to fund operations into 2028.

Shares outstanding were 16,536,069 as of June 30, 2025; this is a baseline figure, not the amount being offered.

RAPT Therapeutics (RAPT) launched a primary offering of common stock via a preliminary prospectus supplement under its Form S-3 shelf. The filing includes a 30-day option for underwriters to purchase additional shares at the public offering price, less underwriting discounts and commissions. RAPT’s stock trades on Nasdaq as “RAPT”; the last reported sale price was $33.67 per share on October 20, 2025.

RAPT intends to use net proceeds, together with existing cash, to advance RPT904 in food allergies and chronic spontaneous urticaria (CSU), support other pipeline initiatives, and for working capital and general corporate purposes. Shares outstanding were 16,536,069 as of June 30, 2025.

RAPT and Jeyou reported positive topline Phase 2 CSU data for RPT904, showing numerically greater UAS7 improvements and higher UAS7=0 rates at Weeks 8, 12 and 16 versus omalizumab, with no serious adverse events related to study drug and no treatment-related discontinuations. The companies plan to discuss Phase 3 development with regulators and to initiate a Phase 2b trial in food allergies before the end of 2025.

RAPT Therapeutics, Inc. has a Schedule 13G disclosure showing Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, beneficially own 951,613 shares of RAPT common stock, representing 5.75% of the outstanding class. The filing states these shares are held by funds and separately managed accounts under Nantahala's control and that none of the Reporting Persons possess sole voting or dispositive power; all voting and dispositive power is shared. The statement affirms the position was acquired and is held in the ordinary course of business and not for the purpose of influencing control of the issuer.

RAPT Therapeutics, Inc. Schedule 13G/A filed by Redmile Group, LLC, Jeremy C. Green and Redmile Biopharma Investments III, L.P. reports beneficial ownership tied to both directly held common stock and exercisable warrants. Redmile Group and Mr. Green report 1,765,303 shares beneficially owned (9.9% of the class) and RBI III reports 1,147,390 shares (6.5% of the class). The filings explain ownership counts after a 1-for-8 reverse stock split and include up to 1,134,617 shares that could be issued upon exercise of certain pre-funded warrants subject to a 9.99% beneficial ownership blocker.

The filing discloses that Redmile Group acts as investment manager to Redmile Funds and that Mr. Green may be deemed to beneficially own the reported securities as principal of Redmile Group. Each reporting person disclaims beneficial ownership except for any pecuniary interest. The statement certifies the holdings are not for the purpose of changing control.